Emeritus Professor Robert Alexander (‘Frank’) Gardiner is a retired academic urologist with an honorary consultant urological appointment at Royal Brisbane & Women’s Hospital and remains based at University of Queensland Centre for Clinical Research for his ongoing research activities. For his international, national and community service activities, research achievements and clinical commitments, he was honoured as a Member, Order of Australia (AM) in 2010, received a Medal & Certificate of Outstanding Service to Fellowship by the Royal Australasian College of Surgeons in 2012 and, in 2014, was presented with a Royal Brisbane and Women’s Hospital (RBWH) Distinguished Research Award and made a Fellow Urological Society of Australia and New Zealand.

EP Gardiner was the first to demonstrate the lymph drainage of the human prostate using lymphoscintigraphy, undertook the first dendritic cell vaccine studies in prostate cancer in Australia (including one Randomised Controlled Trial) and, in the quest for an early non-invasive diagnostic test for prostate cancer, reported the presence of abnormal prostatic cells in ejaculate of 75% of men with prostate cancer. Since 2000, with colleagues, he initiated 3 unique and actively participated in the genesis and running of 6 completed and published randomised controlled trials (RCTs) in South East Queensland. These include the only RCTs, on which he is Principal Investigator, of cognition and androgen deprivation therapy and, more recently, robotic and open prostatectomy.

EP Gardiner’s clinical work was almost exclusively as a consultant urologist at RBWH from 1980 to 2016. During this time, he served as Head of the Urology Unit and Head of the University Department of Surgery. Among other duties, he undertook 7 public clinical sessions per week for the first 19 of these years. He currently is an adjunct professor at Edith Cowan University and previously held adjunct professorial appointments at Griffith University and with Queensland University of Technology.

In addition to roles in formulating prostate cancer guidelines nationally and internationally, EP Gardiner has been an editorial board member of 7 peer-reviewed international journals fulfilling roles as sub-editor and section editor in two and associate editor in another. Between 2005 and 2012, he initiated and instigated Fingertip Urology (FTU) with international colleagues via BJU International (BJUI). FTU was designed to provide props for patient consultations together with Continuing Professional Development (CPD) for Urologists world-wide, being a one-stop shop for up-to-date information for contemporary Urological Practice via the internet. The free primary slides, in particular, consistently received many hits with this initiative firmly establishing the educational credentials of the BJUI journal. Its successor, BJUI Knowledge, is widely accepted for CPD throughout the world.

EP Gardiner was invited to the closed membership of the Urological Research Society in 1997 and served as its president in 2009. As well as being a member of a WHO-sponsored committee in 2000, he was a Foundation Member of Executive of Academic Surgeons of Asia 2000 and was a Member of the Advisory Board of the Asian Pacific Prostate Society (APPS) from 2011: he convened the APPS’ annual scientific meeting in Australia in 2013.

Among other commitments, EP Gardiner was a member of Board of Councillors, Cancer Council Queensland 2004-2015 and a member, Board of Directors, Cancer Council Australia 2010-14: he is honoured to be Patron of the Redlands Branch of Cancer Council Queensland. He was a member from 2008 and served as chairman, Medical & Scientific Research Committee, Prostate Cancer Foundation Australia in 2013, was chairman, Medical and Scientific Advisory Committee, Cancer Council Queensland 2006-15 and chairman and member of Executive, Viertel Cancer Research Centre 2006-15.

From 2001-2019, EP Gardiner was a member of the Board of Andrology Australia and is currently (from 2019) an Advisory Board Member of Healthy Male. He continues as a reviewer of the Question Bank, Royal Australasian College of Surgeons first part examination in Pathology having re-joined in 2016: previously, he was a member of the Pathology Committee 2001-2012 (chairman for the last 3 years) and, for 2 years, a member of the Urology Examination (first part) Committee of the Royal Australasian College of Surgeons. Currently, he is also a member of the Research Advisory Committee of the Royal Brisbane and Women’s Hospital Research Foundation.

Some recent grants

Movember: A Phase II randomised controlled trial of high dose vitamin D in localised prostate cancer with intermediate risk of progression. Gurney H, Nair-Shalliker V, Smith D, Gebski V, Patel M, Frydenberg M, Gardiner RA, Kimlin M, Fenech M, Gillatt D. $1 040 370: 2016-20

NHMRC: ASTROID: Active Surveillance and other treatment options for prostate cancer. Schofield P, Juraskova I, Frydenberg M, Chambers S, Gordon L, Gardiner RA.  $749 704: 2015-2021

Royal Brisbane & Women’s Hospital Foundation. Combined TMPRSS2:ERG PCA3 and SChLAP1 RNA in Urine for selective detection of Aggressive Prostate Cancer. Yaxley J, Koo K, Trau M, Roberts M, Coughlin G, Gianduzzo T, Lavin M, Gardiner R, Mainwaring. $500 000: 2019-24.

NHMRC: Centre for Research Excellence in Prostate Cancer Survivorship. Chambers SK, Newton R, Scuffham P, Baade P, Galvão D, Dunn J, Smith D, Wittert G, Davis I, Gardiner RA (Frank). $$2,498,842. 2016-20.

NHMRC: Improving sexual health in men with prostate cancer: a randomised controlled trial of exercise and psychosocial therapies. Galvao D, Chambers SK, Newton R, Gardiner RA, Cormie P, Spry N, Taafe D, Joseph D, Hamilton. $561 845. 2014-7

Cancer Council Queensland Strategic Research Partnership: A randomised controlled trial of open and robotic prostatectomy: Integrated multidisciplinary studies to guide patient management. Gardiner RA, Chambers SK, Dunglison N, Yaxley J, Occhipinto S, Carter R, Williams S, Lavin MF. $1 490 000: 2008-17